Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH/ISH 2016 | The relationship between basic and clinical research in CML

Giuseppe Saglio • 18 Apr 2016
BSH/ISH 2016
Chronic Myeloid Leukemia Imatinib
DASISION

Giuseppe Saglio, MD of the University of Turin, Turin, Italy discusses the back and forth between basic research and clinical research in relation to the treatment of patients with chronic myeloid leukemia (CML).
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

More from Giuseppe Saglio

Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
1:04
Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
Giuseppe Saglio • 5 Mar 2025
Factors affecting adherence to TKI therapy in patients with CML
1:52
Factors affecting adherence to TKI therapy in patients with CML
Giuseppe Saglio • 5 Mar 2025
The use of asciminib in the frontline treatment of CML
4:12
The use of asciminib in the frontline treatment of CML
Giuseppe Saglio • 5 Mar 2025
Commonly observed side effects with asciminib and how to manage them
1:29
Commonly observed side effects with asciminib and how to manage them
Giuseppe Saglio • 5 Mar 2025

Related Videos

Beyond the label: optimal dosing strategies for CML in community practice
0:51
Beyond the label: optimal dosing strategies for CML in community practice
Fadi Haddad • 10 Sep 2026
Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Optimizing frontline therapy selection to prevent resistance in CML
1:58
Optimizing frontline therapy selection to prevent resistance in CML
Jorge Cortes • 10 Sep 2026
Major breakthroughs in leukemia treatment: precision therapy and immunotherapy
1:19
Major breakthroughs in leukemia treatment: precision therapy and immunotherapy
Iskra Pusic • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals